A Randomized Controlled, Open Label, Adaptive Phase-3 Trial to Evaluate Safety and Efficacy of EndoTAG-1 Plus Gemcitabine Versus Gemcitabine Alone in Patients With Measurable Locally Advanced and/or Metastatic Adenocarcinoma of the Pancreas Failed on FOLFIRINOX Treatment
Not yet recruiting
Phase of Trial: Phase III
Latest Information Update: 29 Mar 2018
At a glance
- Drugs Paclitaxel (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- Sponsors SynCore Biotechnology
- 26 Mar 2018 Planned initiation date changed from 1 Mar 2018 to 1 Jul 2018.
- 21 Mar 2018 Planned initiation date changed from 1 Dec 2017 to 1 Mar 2018.
- 28 Apr 2017 New trial record